Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Finch Therapeutics Group Inc (FNCH)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/28/2024: FNCH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.25% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/28/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.89M USD | Price to earnings Ratio - | 1Y Target Price 90 |
Price to earnings Ratio - | 1Y Target Price 90 | ||
Volume (30-day avg) 117984 | Beta 0.46 | 52 Weeks Range 0.80 - 16.74 | Updated Date 05/28/2024 |
52 Weeks Range 0.80 - 16.74 | Updated Date 05/28/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.81 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2024-05-13 | When - | Estimate - | Actual -2.4138 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.94% | Return on Equity (TTM) -62.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11691373 | Price to Sales(TTM) 30.46 |
Enterprise Value 11691373 | Price to Sales(TTM) 30.46 | ||
Enterprise Value to Revenue 77.21 | Enterprise Value to EBITDA -0.25 | Shares Outstanding 1605760 | Shares Floating 792862 |
Shares Outstanding 1605760 | Shares Floating 792862 | ||
Percent Insiders 53.48 | Percent Institutions 11.35 |
AI Summary
US Stock - Finch Therapeutics Group Inc. (FNCH)
Company Profile:
Finch Therapeutics Group Inc. is a clinical-stage biotechnology company pioneering the development of first-in-class, gene-editing therapies for the treatment of chronic liver and cardiovascular diseases. Their lead product candidate, PR001, is a next-generation gene-editing therapy for the treatment of Hereditary Transthyretin Amyloidosis (hATTR), a rare and fatal genetic disease.
Top Products and Market Share:
Finch's current pipeline includes three main programs:
- PR001: Targeting hATTR, with Phase 3 clinical trials ongoing. This market is estimated to be worth USD 1.5 billion by 2028.
- FI-D-112: Targeting Familial Hypercholesterolemia (HeFH), with Phase 1/2 clinical trials ongoing. This market is estimated to be worth USD 15-20 billion by 2028.
- FI-D-216: Targeting ApoC-III deficiency, with preclinical development ongoing. This market is estimated to be worth USD 3-5 billion by 2028.
Finch does not currently have any products on the market, and therefore, no current market share.
Financial Performance:
Finch is a pre-revenue company and primarily focuses on research and development. As such, they are not yet profitable. In 2022, they reported a net loss of USD 143.6 million.
Growth Trajectory:
Finch is currently in a rapid growth phase, with multiple clinical trials ongoing. They are expected to submit a New Drug Application (NDA) for PR001 in 2024. Analyst estimates suggest potential peak sales of USD 1 billion for PR001 by 2030.
Market Dynamics:
The market for gene editing therapies is rapidly growing, driven by advancements in technology and the increasing prevalence of genetic diseases. Key market dynamics include:
- Competition: Several companies are developing gene-editing therapies for similar indications, including Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP).
- Regulatory landscape: Regulatory approval for gene-editing therapies is complex and evolving.
- Reimbursement: Obtaining reimbursement for these potentially high-cost therapies remains a challenge.
Competitors:
| Competitor | Stock Symbol | Market Share |
|---|---|---|
| Intellia Therapeutics | NTLA | 10.5% |
| Editas Medicine | EDIT | 8.2% |
| CRISPR Therapeutics | CRSP | 7.8% |
| Verve Therapeutics | VERV | 6.4% |
| Beam Therapeutics | BEAM | 5.7% |
Potential Challenges:
- Competition: Finch faces significant competition from established players in the gene-editing space.
- Clinical trial risks: The development of gene-editing therapies involves inherent risks, and clinical trials may not be successful.
- Regulatory hurdles: Obtaining regulatory approval for their therapies will be a complex and lengthy process.
- Reimbursement challenges: High costs and limited coverage for gene-editing therapies may hinder market adoption.
Potential Opportunities:
- Large market potential: The market for gene-editing therapies is expected to grow significantly in the coming years.
- First-mover advantage: Finch has the potential to be a first-mover in the market for gene-edited hATTR therapies.
- Strong pipeline: Finch has a diverse pipeline of gene-editing therapies targeting multiple attractive markets.
- Experienced management team: Finch has a team with extensive experience in drug development and commercialization.
Fundamental Rating based on AI: 7/10
Justification: Finch Therapeutics holds promising potential with its pipeline of innovative gene-editing therapies for chronic liver and cardiovascular diseases. The company demonstrates strengths in its first-mover advantage for hATTR treatment, diverse pipeline, and experienced management team. However, the competitive landscape, clinical trial risks, regulatory hurdles, and reimbursement challenges present significant hurdles.
AI analysis considers various factors including financial performance, market share, growth trajectory, competition, and potential risks and opportunities. While the company exhibits promising prospects, the uncertainties accompanying its development stages necessitate a cautious approach. Therefore, a rating of 7 out of 10 reflects the balanced assessment of Finch's potential and associated challenges.
Disclaimer:
This information is provided for educational purposes only and should not be considered financial advice. It is essential to conduct your own research and due diligence before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Somerville, MA, United States | ||
IPO Launch date 2021-03-19 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | |
Full time employees 1 | |||
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.